Related Experiment Videos
Breast cancer and post-menopausal hormone therapy
1Department of Obstetrics and Gynaecology, Free University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. kenemans@vumc.nl
Summary
Post-menopausal hormone replacement therapy (HRT) use is linked to a small but significant increase in breast cancer risk, with progestogen addition potentially worsening it. Further research is needed on risk factors and alternatives.
Area of Science:
- Endocrinology
- Oncology
- Women's Health
Background:
- Post-menopausal hormone replacement therapy (HRT) has raised concerns regarding breast cancer risk.
- Endogenous estrogen exposure is a known risk factor for breast cancer.
- The mechanisms by which estrogens influence tumor growth and initiation are debated.
Purpose of the Study:
- To review the evidence on the association between HRT and breast cancer risk.
- To explore the role of progestogens in HRT and their impact on breast cancer risk.
- To identify remaining questions and potential alternative therapies.
Main Methods:
- Review of over 60 observational studies.
- Analysis of two randomized trials on HRT and breast cancer.
- Discussion of hormonal mechanisms and risk factors.
Main Results:
- Long-term HRT use is associated with a small but significant increase in breast cancer risk.
- Progestogen addition to HRT does not decrease, and may increase, breast cancer risk.
- Evidence on risk differences between sequential and continuous combined HRT is unclear.
Conclusions:
- Current evidence suggests HRT increases breast cancer risk, with progestogens potentially exacerbating it.
- Further research is needed to clarify risk factors, tumor characteristics, and contraindications for HRT.
- Investigating alternative therapeutic options for menopausal symptoms is warranted.